5 billion people have access to medicine
2 billion to go

The Access to Medicine Foundation stimulates and guides pharmaceutical companies to do more for the people living in low- and middle-income countries without access to medicine.

Quick access

Our research programmes

Access to
Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Visit this programme

Antimicrobial
Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Visit this programme

Access to
Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.

Visit this programme

View all news

Publication - 21 Jan 2020

2020 Antimicrobial Resistance Benchmark

The 2020 Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics.

View all publications

Event - 23 Jan 2020

2020 WEF Annual Meeting: Presenting the 2020 Antimicrobial Resistance Benchmark

On 23 January, the 2nd AMR Benchmark report will be presented for the first time at a dedicated session at the 2020 WEF Annual Meeting in Davos. The session will be opened by Dutch Minister for Medical Care, Mr Bruno Bruins, moderated by Dame Sally Davies

View upcoming events

What leaders say

I’ve been impressed by the Access to Medicine Index. It presents well-balanced stakeholder views on good practices for the pharmaceutical industry and it provides clear standards against which the performance of individual companies can be judged.

Mary Robinson

President, Realizing Rights, Former UN High Commissioner for Human Rights (1997-2002), Former President of Ireland (1990-1997)

When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that.